Edition:
United Kingdom

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

13.95USD
5:20pm GMT
Change (% chg)

$0.23 (+1.68%)
Prev Close
$13.72
Open
$13.84
Day's High
$14.01
Day's Low
$13.76
Volume
4,861
Avg. Vol
34,869
52-wk High
$19.10
52-wk Low
$10.26

Latest Key Developments (Source: Significant Developments)

Oxford Immunotec Sells U.S. Lab Services Business For $170 Mln To Quest Diagnostics - SEC Filing
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Quest Diagnostics Inc ::OXFORD IMMUNOTEC GLOBAL PLC - TO SELL ITS U.S. LABORATORY SERVICES BUSINESS FOR GROSS PROCEEDS OF $170 MILLION IN CASH TO QUEST DIAGNOSTICS - SEC FILING.OXFORD IMMUNOTEC GLOBAL PLC - WILL UPDATE FULL YEAR 2018 REVENUE GUIDANCE UPON CLOSING OF TRANSACTION.  Full Article

Oxford Immunotec Announces Preliminary Revenue For Q4
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Oxford Immunotec Global Plc ::FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S.OXFORD IMMUNOTEC ANNOUNCES PRELIMINARY REVENUE FOR FOURTH QUARTER AND FULL YEAR 2017.SEES FY 2017 REVENUE $103 MILLION TO $103.5 MILLION.SEES Q4 2017 REVENUE $24.9 MILLION TO $25.4 MILLION.Q4 REVENUE VIEW $26.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Oxford Immunotec Global Plc ::OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL - UNDER TERMS OF AGREEMENT, ALL PENDING CLAIMS BETWEEN OXFORD, QIAGEN AND CO-DEFENDANTS HAVE BEEN RESOLVED.OXFORD IMMUNOTEC GLOBAL - CO GRANTED QIAGEN ROYALTY-FREE, NON-EXCLUSIVE LICENSE THAT EXTENDS TO ALL CURRENT AND FUTURE CUSTOMERS OF QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - PATENT INFRINGEMENT IS IN RELATION TO QIAGEN'S QUANTIFERON-TB GOLD AND QUANTIFERON-TB GOLD PLUS PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - OXFORD GRANTED QIAGEN A ROYALTY-FREE, NON-EXCLUSIVE LICENSE IN EXCHANGE FOR A ONE-TIME, LUMP-SUM PAYMENT OF $27.5 MILLION.  Full Article

Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​.Oxford Immunotec Global says ‍second amendment extends term of agreement until December 31, 2023 & establishes pricing - SEC Filing​.  Full Article

Oxford Immunotec Global Q3 loss per share $0.70
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec reports third quarter 2017 financial results.Q3 loss per share $0.70.Sees Q4 2017 revenue $25.4 million to $26.4 million.Q3 revenue $30.4 million versus I/B/E/S view $30 million.Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $103.5 million to $104.5 million.FY2017 revenue view $104.6 million -- Thomson Reuters I/B/E/S.  Full Article